Regulatory Updates

Distribution date: 23 October 2020

The Committee for Veterinary Control and Surveillance of the Ministry of Agriculture of the Republic of Kazakhstan reports outbreak of highly pathogenic avian influenza in the territories of the Tyumen, Kurgan and Saratov regions of the Russian Federation. In this regard, since 30 September 2020 temporary restrictions have been introduced on the importation from Tyumen, Kurgan and Saratov regions (Russian Federation) to the territory of Kazakhstan of live poultry, hatching eggs, down and feathers, poultry meat and all types of poultry products that have not undergone heat treatment (not less than 70°C), feed and feed additives for birds (with the exception of feed additives of chemical and microbiological synthesis), trophies of the chase that have not undergone taxidermy treatment (feather game), as well as used equipment for keeping, slaughtering and cutting birds.

Products Covered: Live poultry, hatching eggs, down and feathers, poultry meat and all poultry products, feed and feed additives for birds, trophies of the chase, used equipment for the maintenance, slaughter and cutting of birds.

Regulation Type: Emergency notifications (SPS)

Distribution date: 22 October 2020 | Final date for Comment: 21 December 2020

The Ministry of Food and Drug Safety (MFDS) of the Republic of Korea is partly revising the “Regulations on Functional Cosmetics Review” (Public Notice issued by the MFDS) for the following purposes: a) to reflect the revised scope of atopy-related functional cosmetics in the “Enforcement Rule of the Cosmetics Act,” (August 2020) which is the superior law, allow human trials on cosmetics for atopy to be conducted by “laboratories for human trials” as for other functional cosmetics b) to record of side effects and actions taken in the human trial of functional cosmetics in accordance with the provision on human trials in the “Regulation on Substantiation of Claims in Labeling or Advertising of Cosmetic Products”; c) to provide a legal ground for partial exemption of data submission for the review of the “cosmetics that help relieve hair loss symptoms” under Article 2 subparagraph 8 of the “Enforcement Rules of the Cosmetics Act”; d) to revise terminology (e.g. responsible cosmetic seller) and references to provisions in accordance with the changes in other relevant regulations

Products Covered: Cosmetics

Regulation Type: Regular notification

Distribution date: 22 October 2020 | Final date for Comment: 21 December 2020

The Ministry of Food and Drug Safety (MFDS) of the Republic of Korea is partly revising the “Regulations on Functional Cosmetics Review” (Public Notice issued by the MFDS) for the following purposes: a) to reflect the revised scope of atopy-related functional cosmetics in the “Enforcement Rule of the Cosmetics Act,” (August 2020) which is the superior law, allow human trials on cosmetics for atopy to be conducted by “laboratories for human trials” as for other functional cosmetics b) to record of side effects and actions taken in the human trial of functional cosmetics in accordance with the provision on human trials in the “Regulation on Substantiation of Claims in Labeling or Advertising of Cosmetic Products”; c) to provide a legal ground for partial exemption of data submission for the review of the “cosmetics that help relieve hair loss symptoms” under Article 2 subparagraph 8 of the “Enforcement Rules of the Cosmetics Act”; d) to revise terminology (e.g. responsible cosmetic seller) and references to provisions in accordance with the changes in other relevant regulations

Products Covered: Cosmetics

Regulation Type: Regular notification

Distribution date: 22 October 2020 | Final date for Comment: 21 December 2020

Ministry of Health and Labour and Welfare will abolish the Japanese Pharmacopoeia Seventeenth edition and establish Eighteenth edition under Paragraph 1 of Article 41 of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, the Japanese Pharmacopoeia, Seventeenth edition are to be revised.

Products Covered: Pharmaceutical Products (HS:30)

Regulation Type: Regular notification

Distribution date: 22 October 2020 | Final date for Comment: 21 December 2020

Ministry of Health and Labour and Welfare will abolish the Japanese Pharmacopoeia Seventeenth edition and establish Eighteenth edition under Paragraph 1 of Article 41 of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, the Japanese Pharmacopoeia, Seventeenth edition are to be revised.

Products Covered: Pharmaceutical Products (HS:30)

Regulation Type: Regular notification

Distribution date: 20 October 2020

The Annex I of the Resolution – RDC number 405, 22 July 2020 – previously notified through G/TBT/N/BRA/1061 – which establishes control measures for medicines that contain substances mentioned by the Annex I of this resolution, isolated or in association with other drugs, due to the international public health emergency of the new coronavirus (SARS-CoV-2), was changed by the Resolution – RDC number 420, 1 September 2020. 

Products Covered:

Regulation Type: Addendum to Regular Notification

Distribution date: 20 October 2020

The Annex I of the Resolution – RDC number 405, 22 July 2020 – previously notified through G/TBT/N/BRA/1061 – which establishes control measures for medicines that contain substances mentioned by the Annex I of this resolution, isolated or in association with other drugs, due to the international public health emergency of the new coronavirus (SARS-CoV-2), was changed by the Resolution – RDC number 420, 1 September 2020. 

Products Covered:

Regulation Type: Addendum to Regular Notification

Distribution date: 20 October 2020 | Final date for Comment: 19 November 2020

(1) The Minimum Requirements for Biological Products shall be partially amended to add the standard for a blood product to be newly approved. (2) The Public Notice on National Release Testing shall be partially amended to provide for the above-mentioned blood product.

Products Covered: Pharmaceutical Products (HS: 30)

Regulation Type: Regular notification

Distribution date: 20 October 2020 | Final date for Comment: 19 November 2020

(1) The Minimum Requirements for Biological Products shall be partially amended to add the standard for a blood product to be newly approved. (2) The Public Notice on National Release Testing shall be partially amended to provide for the above-mentioned blood product.

Products Covered: Pharmaceutical Products (HS: 30)

Regulation Type: Regular notification

Distribution date: 20 October 2020 | Final date for Comment: 19 December 2020

The Ministry of Food and Drug Safety of the Republic of Korea is partly revising the “Pharmaceutical Affairs Act”. The main contents are: For the pharmaceutical imported, similar to pharmaceutical manufactured, the distribution has been managed thoroughly by prescribing the prohibition another pharmaceutical that is not identical with the approved and reported information such as ingredient and amount from importing, storing and displaying for the purpose of marketing. Under “Safety Control Act of Household Chemicals and Biocidal Product” (Established on 20 Mar 2018; Implemented on 1 Jan 2019), the managing body shall be excluded in the scope of quasi-drug as nematicide and humidifier disinfectant of fly and mosquito that were controlled as quasi-drug according to “Pharmaceutical Affairs Act” was changed. (Article 2, 62 and 68-4)

Products Covered: Pharmaceuticals, Quasi-drug

Regulation Type: Regular notification